In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Buy rating on PAVmed (PAVM – Research Report), with a price target of $1.50. The company’s shares opened today at $0.47.
Vendetti covers the Healthcare sector, focusing on stocks such as Cutera, Nephros, and Dermata Therapeutics. According to TipRanks, Vendetti has an average return of -1.2% and a 34.67% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for PAVmed with a $4.63 average price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $2.34 and a one-year low of $0.35. Currently, PAVmed has an average volume of 416.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PAVmed, Inc. is a medical device company, which develops and commercializes a pipeline of medical products. Its product portfolio includes DisappEAR, PORTIO, Caldus, Carpx, NextCath, and NextFlo. The company was founded on June 26, 2014 and is headquartered in New York, NY.
Read More on PAVM:
